WAVE Life Sciences Ltd

The stock is building an early Stage 1 base after the panic-driven flush, with price tightly tracking above the rising 9 and 21 EMAs and showing stabilization. The Post-Capitulation pattern confirms exhaustion of selling pressure, supporting a medium-term bullish bias ahead of a potential Stage 2 transition. Short-term execution is favorable as momentum remains positive and no overbought signals are evident. Participation now at EMA support aligns with the momentum-oriented strategy seeking continuation.

• ↑Q1 2026 revenue rose 315% YoY to $38.2 M, driven by WVE-006/007.
• ↑Phase 1 WVE-007 cut visceral fat 14.3% and total fat 5.3%.
• ↓Q1 net loss of $26.1 M reflects ongoing unprofitability.